Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Drugpatentwatch crizotinib?
Patent expiry trametinib?
What's the advised delay for milk post lipitor?
Pramlintide approval date?
Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?

Tadalafil patent?

See the DrugPatentWatch profile for Tadalafil

Tadalafil is the active ingredient in Cialis (for ED/BPH) and Adcirca (for PAH). It was originally developed by ICOS Corporation and later licensed to Eli Lilly.

Key points about the patent status (jurisdiction-dependent and subject to change):
- The core tadalafil compound and its main uses were protected by a family of patents owned by Eli Lilly/ICOS.
- In many major markets (e.g., United States, Europe), the primary tadalafil patents and key use patents have expired or are expiring around the late 2010s to early 2020s, which enabled or accelerated the entry of generics.
- There are still other patents that can cover:
- specific formulations or dosage forms.
- methods of use for particular conditions.
- the PAH indication (Adcirca) and related claims, which may extend protection in some jurisdictions.
- Because patent terms and extensions (including pediatric exclusivity and term adjustments) vary by country, exact expiry dates are jurisdiction-specific.

If you want, tell me a country or region and I can look up the current status in that jurisdiction (and provide links to the relevant patent databases). I can also give you approximate expiry timelines for that area.

Other Questions About Tadalafil :

where is tadalafil manufactured Teva tadalafil approval japan? Tadalafil brand? Tadalafil expiration? Tadalafil 20mg best price? Tadalafil 5mg price overview? Tadalafil brands in india?

AI-Drug Label Prescribing Information Alignment Report

100

100%

Grade A

Excellent

Excellent

Patient Risk: Low

Summary

All extracted claims were evaluated against the FDA label. Only the Adcirca PAH claim is supported by the label (section 14.1). All other claims are not present in the provided label.

Category Scores

Indication

100

Excellent

Accurate Statements

Tadalafil is the active ingredient in Adcirca (for PAH).

Section 14.1

Unsupported Statements

Tadalafil is the active ingredient in Cialis (for ED/BPH).

Not present in FDA labeling provided.

Tadalafil was originally developed by ICOS Corporation.

Not present in FDA labeling provided.

Tadalafil was later licensed to Eli Lilly.

Not present in FDA labeling provided.

The core tadalafil compound was protected by a family of patents owned by Eli Lilly/ICOS.

Not present in FDA labeling provided.

Tadalafil's main uses were protected by a family of patents owned by Eli Lilly/ICOS.

Not present in FDA labeling provided.

In many major markets (e.g., United States, Europe), the primary tadalafil patents have expired.

Not present in FDA labeling provided.

In many major markets (e.g., United States, Europe), the key use patents have expired.

Not present in FDA labeling provided.

This expiration enabled or accelerated the entry of generics.

Not present in FDA labeling provided.

There are still other patents that can cover specific formulations or dosage forms.

Not present in FDA labeling provided.

There are still other patents that can cover methods of use for particular conditions.

Not present in FDA labeling provided.

There are still other patents that can cover the PAH indication (Adcirca) and related claims.

Not present in FDA labeling provided.

These PAH-related patents may extend protection in some jurisdictions.

Not present in FDA labeling provided.

Patent terms and extensions (including pediatric exclusivity and term adjustments) vary by country.

Not present in FDA labeling provided.

Exact expiry dates are jurisdiction-specific.

Not present in FDA labeling provided.

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low

Regulatory Assessment

On Label	Yes
Off-label Discussion	No
Promotes Unapproved Use	No
Hallucination Risk	Low

Recommendation

Excellent

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score

58

Visibility

50

Mentioned

Ranking

#1

Sentiment

50

Recommendation Status

mentioned only

Brand Perception

Best Known For

The active ingredient in Cialis (for ED/BPH) and Adcirca (for PAH).

Core Claims

The core tadalafil compound and its main uses were protected by a family of patents owned by Eli Lilly/ICOS.
In many major markets (e.g., United States, Europe), the primary tadalafil patents and key use patents have expired or are expiring around the late 2010s to early 2020s, which enabled or accelerated the entry of generics.
There are still other patents that can cover specific formulations or dosage forms, methods of use for particular conditions, the PAH indication (Adcirca).
Because patent terms and extensions vary by country, exact expiry dates are jurisdiction-specific.

Differentiators

Tadalafil is the active ingredient in Cialis (for ED/BPH) and Adcirca (for PAH).
Primary tadalafil patents and related use patents have expired or are expiring in many major markets.
Some jurisdictions may still cover formulations, dosage forms, and methods of use for tadalafil.

Pricing Perception: Not Mentioned